APA (7th ed.) Citation

Hasni, S. A., Gupta, S., Davis, M., Poncio, E., Temesgen-Oyelakin, Y., Carlucci, P. M., . . . Kaplan, M. J. (2021). Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature communications, 12(1), 3391-11. https://doi.org/10.1038/s41467-021-23361-z

Chicago Style (17th ed.) Citation

Hasni, Sarfaraz A., et al. "Phase 1 Double-blind Randomized Safety Trial of the Janus Kinase Inhibitor Tofacitinib in Systemic Lupus Erythematosus." Nature Communications 12, no. 1 (2021): 3391-11. https://doi.org/10.1038/s41467-021-23361-z.

MLA (9th ed.) Citation

Hasni, Sarfaraz A., et al. "Phase 1 Double-blind Randomized Safety Trial of the Janus Kinase Inhibitor Tofacitinib in Systemic Lupus Erythematosus." Nature Communications, vol. 12, no. 1, 2021, pp. 3391-11, https://doi.org/10.1038/s41467-021-23361-z.